Literatur
King TE Jr et al. N Engl J Med. 2014;371(8):783–4
Richeldi L et al. N Engl J Med. 2014;371(8):783
Ogura T et al. Eur Respir J. 2015;45(5):1382–92
Taniguchi et al. Eur Resp J. 2016 (Abstract)
Flaherty KR et al. Am J Respir Crit Care Med. 2017 (Abstract)
Behr J et al. Pneumologie. 2017;71(7):460–74
Originalie
Vancheri C, Kreuter M, Richeldi L et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis: Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2017 Sep 10, https://doi.org/10.1164/rccm.201706-1301OC
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Markart, P., Günther, A. Akzeptable Sicherheit und Verträglichkeit. Pneumo News 10, 17–18 (2018). https://doi.org/10.1007/s15033-018-0860-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15033-018-0860-8